Ionis Pharmaceuticals, Inc. Induced Conversion of Convertible Debt Expense
Ionis Pharmaceuticals, Inc. (IONS) reported Induced Conversion of Convertible Debt Expense of $16.34 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InducedConversionOfConvertibleDebtExpense · last filed 2026-02-26
- Ionis Pharmaceuticals, Inc. induced conversion of convertible debt expense for fiscal 2025 was $16.34M.
- Ionis Pharmaceuticals, Inc. induced conversion of convertible debt expense for fiscal 2024 was $0.00.
- Ionis Pharmaceuticals, Inc. induced conversion of convertible debt expense for fiscal 2023 was $0.00.
| Period end | Induced Conversion of Convertible Debt Expense 12 month |
|---|---|
| 2025-12-31 | $16.34M 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |